FindTrial
Sign In

To assess how effective Empagliflozin and Midodrine are in treating patients with refractory ascites.

Efficacy of Empagliflozin and Midodrine in refractory ascites - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079132
Enrollment
66
Registered
2025-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Kasturba medical college MAHE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 18 to 75 years. Decompensated liver cirrhosis with refractory ascites.

Exclusion criteria

Exclusion criteria: Patient with contraindication to midodrine and empagliflozin. Systemic Hypertension Pregnant or breastfeeding women. History of hypoglycemia. History of recurrent urinary tract infection.

Design outcomes

Primary

MeasureTime frame
Mean change in abdominal girth from baseline to 12 weeks- Abdominal girth will be measured as surrogate for ascites volume. Mean change in body weight from baseline to 12 weeks. Mean change in the grading of ascitesTimepoint: 0,4,8,12 months—

Secondary

MeasureTime frame
Worsening of hepatic encephalopathy Worsening of CTP and MELD function Frequency of other complications of cirrhosis - variceal hemorrhage or development of hepato-renal syndrome and hospitalization Adverse effects Mortality from complications of cirrhosisTimepoint: 0,4,8,12 months—

Countries

India

Contacts

Public ContactDr V S Mohammed Fazil

Manipal Academy of Higher Education

bhat.ganesh@manipal.edu9900791615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026